Skip to main content

Incyte Value Stock - Dividend - Research Selection


ISIN: US45337C1027, WKN: 896133

Market price date: 26.01.2022
Market price: 73,52 USD

Incyte Fundamental data and company key figures of the share

Annual reports in USD
Key figures 12-02-2021
Cash flow
Net operating cash flow -124.599.000
Capital Expenditures -187.379.000
Free cash flow -311.977.984
Balance sheet
Total Equity 2.611.270.000
Liabilities & Shareholders equity 3.560.920.000
Income statement
Net income -295.697.000
Eps (diluted) -1,360
Diluted shares outstanding 219.000.000
Net sales/revenue 2.666.700.000

Fundamental ratios calculated on: 26-01-2022

Key figures 26-01-2022
Cash flow
P/C -129,22
P/FC -51,61
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization16.100.880.384,00 USD
CountryUnited States
IndicesNASDAQ 100,NASDAQ Comp.,S&P 500,MSCI World Index
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-09-01,2.0000/1.0000; 1997-11-10,2.0000/1.0000

Description of the company

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus - Benzinga

Incyte Corporation (NASDAQ: INCY) is 

Incyte Says Withdrawing NDA for Parsaclisib Is a 'Business Decision'

By Stephen Nakrosis Biopharmaceutical company Incyte Corp. on Tuesday said it was withdrawing its new drug application for parsaclisib to treat certain lymphoma patients following discussions... | January 25, 2022

Incyte Provides Update on Parsaclisib and MCLA-145

Incyte today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta , and MCLA-145, its... | January 25, 2022

District Court Denies Motion To Dismiss SEC's First ‘Shadow Trading' Complaint

Judge William H. Orrick of the Northern District of California recently denied a motion to dismiss the Securities and Exchange Commission's first insider trading case charging a defendant with... | January 25, 2022

2 Beaten-Down Cathie Wood Growth Stocks to Buy and Hold For 10 Years

Even the best investors don't always beat the market over relatively short periods, say 12 months, for instance. Case in point: Last year Cathie Wood, CEO of the asset management company ARK Invest, was one big name in the investing world whose actively managed, exchange-traded f

Sierra Oncology's bone marrow cancer drug meets study main goal

Sierra Oncology Inc said on Tuesday its experimental drug for anemic patients with a type of bone marrow cancer met the main goal of reducing disease symptoms and also cut patients' dependence on blood transfusions, in a late-stage trial.

What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020

U.S. stock futures indicated more losses to start the new week following the Nasdaq's and the S&P 500's worst weeks since March 2020.

Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more

The stocks making the biggest moves in premarket trading include Kohl's, Snap, Peloton, and more.

'Shadow Trading' Case Survives Defendant's Motion To Dismiss

The U.S. District Court for the Northern District of California in SEC v. Panuwat, a case we discussed in a previous blog as having significant repercussions for insider trading enforcement in fiscal... | January 24, 2022

Innovent : Pemazyre Approved In Hong Kong For Treatment Of Adults With Metastatic Cholangiocarcinoma

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) said Monday that the Hong Kong Department of Health has approved Pemazyre or pemigatinib for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or